R-Golix 120mg Tablet

• Treatment of Advanced Prostate cancer

R-Golix 120mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.

Common side effects include:

• Fatigue
• Increased aspartate aminotransferase
• Constipation
• Diarrhea
• Increased hemoglobin
• Increased alanine aminotransferase
• Hot flashes
• Increased glucose level in blood
• Increased triglyceride level in blood
• Musculoskeletal (bone, muscle or joint) pain

Seek medical attention in case of any unusual or severe side effects immediately.

• The dosage and duration of the R-Golix 120mg Tablet are decided by the doctor based on the severity of the infection and other health factors. This tablet can be taken with or without food but take it at the same time everyday for better results.
• Before starting this medicine, please inform your doctor about your medical history. If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.​
  

• R-Golix 120mg Tablet is an anticancer medicine with active ingredient Relugolix which is a GnRH receptor antagonist. It inhibits the growth & multiplication of cancer cells by lowering the level of testosterone produced in the body.
• As this medicine works by blocking the pituitary gland from releasing luteinizing hormone & FSH, and reducing androgen production.
  

• Motlagh, R. S., Abufaraj, M., Mori, K., Aydh, A., Rajwa, P., Katayama, S., ... & Shariat, S. F. (2022). The efficacy and safety of relugolix compared with degarelix in advanced prostate cancer patients: a network meta-analysis of randomized trials. European urology oncology, 5(2), 138-145. https://pubmed.ncbi.nlm.nih.gov/34301529/
• Saad, F., & Shore, N. D. (2021). Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology, 13, 1758835921998586. https://pubmed.ncbi.nlm.nih.gov/34408793/
• Sahu, K. K., Tripathi, N., Agarwal, N., & Swami, U. (2022). Relugolix in the management of prostate cancer. Expert Review of Anticancer Therapy, 22(9), 891-902. https://pubmed.ncbi.nlm.nih.gov/35866612/
• Spratt, D. E., George, D. J., Shore, N. D., Cookson, M. S., Saltzstein, D. R., Tutrone, R., ... & Tombal, B. F. (2024). Efficacy and safety of radiotherapy plus relugolix in men with localized or advanced prostate cancer. JAMA oncology, 10(5), 594-602. https://pubmed.ncbi.nlm.nih.gov/38451492/
• Shore, N. D., Saad, F., Cookson, M. S., George, D. J., Saltzstein, D. R., Tutrone, R., ... & Tombal, B. (2020). Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. New England Journal of Medicine, 382(23), 2187-2196.